AACR 2026: Revolution's next prospect, Merck's reveal and a lung cancer battle [Yahoo! Finance]
Revolution Medicines (RVMD) had its "buy" rating reaffirmed by Stifel Nicolaus. They now have a $215.00 price target on the stock, up from $170.00.
After a year of turmoil, cancer researchers see promising signs for mRNA vaccines [CNN]
After a year of turmoil, cancer researchers see promising signs for mRNA vaccines [CNN]
Revolution Medicines (RVMD) Jumps 54% on Stellar Drug Trial Results [Yahoo! Finance]